U.S. flag

An official website of the United States government

NM_000551.4(VHL):c.233A>G (p.Asn78Ser) AND Von Hippel-Lindau syndrome

Germline classification:
Pathogenic (5 submissions)
Last evaluated:
Jun 25, 2024
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000079207.21

Allele description [Variation Report for NM_000551.4(VHL):c.233A>G (p.Asn78Ser)]

NM_000551.4(VHL):c.233A>G (p.Asn78Ser)

Gene:
VHL:von Hippel-Lindau tumor suppressor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
3p25.3
Genomic location:
Preferred name:
NM_000551.4(VHL):c.233A>G (p.Asn78Ser)
Other names:
NM_000551.4(VHL):c.233A>G
HGVS:
  • NC_000003.12:g.10142080A>G
  • NG_008212.3:g.5446A>G
  • NM_000551.4:c.233A>GMANE SELECT
  • NM_001354723.2:c.233A>G
  • NM_198156.3:c.233A>G
  • NP_000542.1:p.Asn78Ser
  • NP_000542.1:p.Asn78Ser
  • NP_001341652.1:p.Asn78Ser
  • NP_937799.1:p.Asn78Ser
  • LRG_322t1:c.233A>G
  • LRG_322:g.5446A>G
  • LRG_322p1:p.Asn78Ser
  • NC_000003.11:g.10183764A>G
  • NM_000551.3:c.233A>G
  • P40337:p.Asn78Ser
  • p.[Asn78Ser]
Protein change:
N78S
Links:
UniProtKB: P40337#VAR_005683; dbSNP: rs5030804
NCBI 1000 Genomes Browser:
rs5030804
Molecular consequence:
  • NM_000551.4:c.233A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354723.2:c.233A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_198156.3:c.233A>G - missense variant - [Sequence Ontology: SO:0001583]
Observations:
5

Condition(s)

Name:
Von Hippel-Lindau syndrome (VHLS)
Synonyms:
VHL syndrome; Von Hippel-Lindau
Identifiers:
MONDO: MONDO:0008667; MedGen: C0019562; Orphanet: 892; OMIM: 193300

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000264678Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia
no assertion criteria provided
Pathogenic
(Feb 26, 2016)
germlineclinical testing

SCV000785647Counsyl
criteria provided, single submitter

(Counsyl Autosomal Dominant Disease Classification criteria (2015))
Pathogenic
(Oct 19, 2017)
unknownclinical testing

PubMed (14)
[See all records that cite these PMIDs]

Counsyl_Autosomal_Dominant_Disease_Classification_criteria_(2015)_v1.pdf,

Citation Link,

SCV001442590Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Oct 28, 2020)
germlineclinical testing

PubMed (6)
[See all records that cite these PMIDs]

Citation Link,

SCV001950147Clinical Genomics Labs, University Health Network
no assertion criteria provided

(ACMG Guidelines, 2015)
Pathogenic
(Jul 10, 2019)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV005187307ClinGen VHL Variant Curation Expert Panel, ClinGen
reviewed by expert panel

(ClinGen VHL VCEP ACMG Specifications VHL V1)
Pathogenic
(Jun 25, 2024)
germlinecuration

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyes5not providednot providednot providednot providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation

Citations

PubMed

p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees.

Qi XP, Liu WT, Li JY, Dai Y, Ma JM, Zhao Y, Fei J, Li F, Shen M, Jin HY, Chen ZG, Du ZF, Chen XL, Zhang XN.

Mol Med Rep. 2013 Sep;8(3):799-805. doi: 10.3892/mmr.2013.1578. Epub 2013 Jul 9.

PubMed [citation]
PMID:
23842656

Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients.

Peng S, Shepard MJ, Wang J, Li T, Ning X, Cai L, Zhuang Z, Gong K.

Oncotarget. 2017 Jun 13;8(24):38456-38465. doi: 10.18632/oncotarget.16594.

PubMed [citation]
PMID:
28388566
PMCID:
PMC5503545
See all PubMed Citations (18)

Details of each submission

From Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia, SCV000264678.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided5not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot provided5not providednot providednot provided

From Counsyl, SCV000785647.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (14)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001442590.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (6)

Description

Variant summary: VHL c.233A>G (p.Asn78Ser) results in a conservative amino acid change located in the von Hippel-Lindau disease tumour suppressor, beta domain (IPR024053) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 230680 control chromosomes (gnomAD). c.233A>G has been reported in the literature in multiple individuals affected with Von Hippel-Lindau Syndrome and has been shown to co-segregate with disease in different families (e.g. Zbar_1996, Cybulski_2002, Dollfus_2002, Huang_2004). These data indicate that the variant is very likely to be associated with disease. Experimental evidence demonstrated the variant impairs protein function and stability and results in compromised tight junction formation, disorganized cell morphology and increased HIF (hypoxia-inducible factor) activation (e.g. Bangiyeva_2009, Bond_2011). Seven ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Clinical Genomics Labs, University Health Network, SCV001950147.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From ClinGen VHL Variant Curation Expert Panel, ClinGen, SCV005187307.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (1)

Description

The variant NM_000551.4(VHL):c.233A>G (p.Asn78Ser) is a missense variant predicted to cause substitution of Asparagine by Serine. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). This is identified in over 16 probands meeting either Danish criteria for VHL, or harboring other consistent features with VHL. The total phenotype points is 15.25, which meets the VHL VCEP specification of PS4 (5-15 phenotype points) (PMIDs:728151; 23842656; 25952756; 21463266; 25078357; 8634692; 23407287; 8707293; 8730290; 18067796; 12114495; 12202531; 17024664; 28388566; 18446368; 10567493; 29294023; 11850829) This variant has been identified as a de novo occurrence with unconfirmed parental relationships in 1 individual with VHL (PMID:12114495) (PM6). This variant is also seen 4 times in cancerhotspots.org, which meets the criteria of PM1_Supporting, when using somatic data to inform a germline variant curation. However, as the variant resides in the first Beta domain of VHL, a critical functional domain, it meets the full moderate criteria of (PM1). Functional data shows this variant did not alter expression of HIF1a (102% for HIF1α , similar to the truncating control used) and 86% expression for HIF2α (PS3_Supporting; PMID:21715564). The computational predictor REVEL gives a score of 0.767, which is above the threshold of >0.664, evidence that correlates with impact to VHL function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal-dominant von Hippel Lindau syndrome (VHL syndrome) based on the ACMG/AMP criteria applied, as specified by the ClinGen VHL VCEP Version 1.0 (Specifications approval date: 02/26/2024. Variant Approval Date 06/25/2024).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 13, 2024